Procter & Gamble Health Share Price
Sector: Biotechnology & Drugs
5905.15 +28.85 (0.49%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
5874.20
Today’s High
5940.50
52 Week Low
4912.30
52 Week High
6107.55
5921.00 +65.50 (1.12%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
5852.50
Today’s High
5943.50
52 Week Low
4863.00
52 Week High
6175.50
Key Metrics
- Market Cap (In Cr) 9888.51
- Beta 0.56
- Div. Yield (%) 3.12
- P/B 18.26
- TTM P/E 34.01
- Sector P/E 22.43
- D/E 0
- Open Price 5876.3
- Prev Close 5876.3
Procter & Gamble Health Analysis
Price Analysis
-
1 Week0.24%
-
3 Months15.05%
-
6 Month11.99%
-
YTD13.04%
-
1 Year17.67%
Risk Meter
- 27% Low risk
- 27% Moderate risk
- 27% Balanced Risk
- 27% High risk
- 27% Extreme risk
Procter & Gamble Health News
P&G Hygiene sees rebound in rural demand, but urban stress persists
3 min read . 12 Jun 2025Q4 results today: LIC, Info Edge, Minda Corp, Supriya Lifesciences, Bosch, more
2 min read . 27 May 2025Dividend Stocks: Oil India, HAL, among others to trade ex-dividend next week
3 min read . 16 Feb 2025Procter & Gamble Health Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2024
- Total Revenue
- 1151.26
- Selling/ General/ Admin Expenses Total
- 422.39
- Depreciation/ Amortization
- 27.05
- Other Operating Expenses Total
- 16.09
- Total Operating Expense
- 892.85
- Operating Income
- 258.41
- Net Income Before Taxes
- 273.32
- Net Income
- 200.98
- Diluted Normalized EPS
- 131.22
- Period
- 2024
- Total Assets
- 794.36
- Total Liabilities
- 256.12
- Total Equity
- 538.24
- Tangible Book Valueper Share Common Eq
- 323.67
- Period
- 2024
- Cashfrom Operating Activities
- 228.29
- Cashfrom Investing Activities
- -6.87
- Cashfrom Financing Activities
- -418.11
- Net Changein Cash
- -196.69
- Period
- 2023
- Total Revenue
- 1229.62
- Selling/ General/ Admin Expenses Total
- 436.37
- Depreciation/ Amortization
- 27.76
- Other Operating Expenses Total
- 16.63
- Total Operating Expense
- 933.04
- Operating Income
- 296.58
- Net Income Before Taxes
- 314.2
- Net Income
- 229.47
- Diluted Normalized EPS
- 143.18
- Period
- 2023
- Total Assets
- 1101.19
- Total Liabilities
- 350.3
- Total Equity
- 750.89
- Tangible Book Valueper Share Common Eq
- 451.79
- Period
- 2023
- Cashfrom Operating Activities
- 235.99
- Cashfrom Investing Activities
- -21.5
- Cashfrom Financing Activities
- -98.47
- Net Changein Cash
- 116.02
- Period
- 2022
- Total Revenue
- 1114.41
- Selling/ General/ Admin Expenses Total
- 412.9
- Depreciation/ Amortization
- 26.73
- Other Operating Expenses Total
- 9.96
- Total Operating Expense
- 873.27
- Operating Income
- 241.14
- Net Income Before Taxes
- 253.37
- Net Income
- 192.52
- Diluted Normalized EPS
- 118.93
- Period
- 2022
- Total Assets
- 888.12
- Total Liabilities
- 271.63
- Total Equity
- 616.49
- Tangible Book Valueper Share Common Eq
- 371.37
- Period
- 2022
- Cashfrom Operating Activities
- 169.53
- Cashfrom Investing Activities
- -25.54
- Cashfrom Financing Activities
- -288.63
- Net Changein Cash
- -144.64
- Period
- 2021
- Total Revenue
- 1008.73
- Selling/ General/ Admin Expenses Total
- 405.06
- Depreciation/ Amortization
- 29.69
- Other Operating Expenses Total
- 7.9
- Total Operating Expense
- 792.33
- Operating Income
- 216.4
- Net Income Before Taxes
- 233.28
- Net Income
- 176.8
- Diluted Normalized EPS
- 106.92
- Period
- 2021
- Total Assets
- 986.16
- Total Liabilities
- 282.45
- Total Equity
- 703.71
- Tangible Book Valueper Share Common Eq
- 423.87
- Period
- 2021
- Cashfrom Operating Activities
- 247.26
- Cashfrom Investing Activities
- -32.27
- Cashfrom Financing Activities
- -386.63
- Net Changein Cash
- -171.64
- Period
- 2020
- Total Revenue
- 1355.86
- Selling/ General/ Admin Expenses Total
- 488.14
- Depreciation/ Amortization
- 28.93
- Other Operating Expenses Total
- 7.19
- Total Operating Expense
- 1066.65
- Operating Income
- 289.21
- Net Income Before Taxes
- 354.85
- Net Income
- 254.08
- Diluted Normalized EPS
- 154.47
- Period
- 2020
- Total Assets
- 1175.74
- Total Liabilities
- 269.4
- Total Equity
- 906.34
- Tangible Book Valueper Share Common Eq
- 545.88
- Period
- 2020
- Cashfrom Operating Activities
- 235.37
- Cashfrom Investing Activities
- 164.64
- Cashfrom Financing Activities
- -883.41
- Net Changein Cash
- -483.4
- Period
- 2018
- Total Revenue
- 848.99
- Selling/ General/ Admin Expenses Total
- 362.91
- Depreciation/ Amortization
- 21.12
- Other Operating Expenses Total
- 2.65
- Total Operating Expense
- 721.96
- Operating Income
- 127.03
- Net Income Before Taxes
- 157.98
- Net Income
- 838.72
- Diluted Normalized EPS
- 58.45
- Period
- 2018
- Total Assets
- 1759.46
- Total Liabilities
- 219.35
- Total Equity
- 1540.11
- Tangible Book Valueper Share Common Eq
- 927.55
- Period
- 2018
- Cashfrom Operating Activities
- -130.38
- Cashfrom Investing Activities
- 1269.72
- Cashfrom Financing Activities
- -30.05
- Net Changein Cash
- 1109.29
- Period
- 2025-03-31
- Total Revenue
- 310.99
- Selling/ General/ Admin Expenses Total
- 48.79
- Depreciation/ Amortization
- 5.37
- Other Operating Expenses Total
- 82.56
- Total Operating Expense
- 235.44
- Operating Income
- 75.55
- Net Income Before Taxes
- 78.53
- Net Income
- 61.18
- Diluted Normalized EPS
- 36.86
- Period
- 2025-03-31
- Total Assets
- 794.2
- Total Liabilities
- 257.24
- Total Equity
- 536.96
- Tangible Book Valueper Share Common Eq
- 323.05
- Period
- 2025-03-31
- Cashfrom Operating Activities
- 168.69
- Cashfrom Investing Activities
- 9.59
- Cashfrom Financing Activities
- -234.74
- Net Changein Cash
- -56.46
- Period
- 2024-12-31
- Total Revenue
- 309.77
- Selling/ General/ Admin Expenses Total
- 47.05
- Depreciation/ Amortization
- 5.55
- Other Operating Expenses Total
- 63.56
- Total Operating Expense
- 191.89
- Operating Income
- 117.88
- Net Income Before Taxes
- 121.69
- Net Income
- 90.9
- Diluted Normalized EPS
- 54.76
- Period
- 2024-12-31
- Total Assets
- 870.15
- Total Liabilities
- 259.69
- Total Equity
- 610.46
- Tangible Book Valueper Share Common Eq
- 367.25
- Period
- 2024-12-31
- Cashfrom Operating Activities
- 119.47
- Cashfrom Investing Activities
- 9.64
- Cashfrom Financing Activities
- -101.16
- Net Changein Cash
- 27.95
- Period
- 2024-09-30
- Total Revenue
- 313.41
- Selling/ General/ Admin Expenses Total
- 46.22
- Depreciation/ Amortization
- 5.77
- Other Operating Expenses Total
- 65.1
- Total Operating Expense
- 205.14
- Operating Income
- 108.27
- Net Income Before Taxes
- 111.4
- Net Income
- 82.33
- Diluted Normalized EPS
- 49.6
- Period
- 2024-09-30
- Period
- 2024-09-30
- Period
- 2024-06-30
- Total Revenue
- 283.88
- Selling/ General/ Admin Expenses Total
- 48.63
- Depreciation/ Amortization
- 7.16
- Other Operating Expenses Total
- 107.83
- Total Operating Expense
- 262.98
- Operating Income
- 20.9
- Net Income Before Taxes
- 22.83
- Net Income
- 16.78
- Diluted Normalized EPS
- 19.03
- Period
- 2024-06-30
- Total Assets
- 794.36
- Total Liabilities
- 256.12
- Total Equity
- 538.24
- Tangible Book Valueper Share Common Eq
- 323.67
- Period
- 2024-06-30
- Cashfrom Operating Activities
- 228.29
- Cashfrom Investing Activities
- -6.87
- Cashfrom Financing Activities
- -418.11
- Net Changein Cash
- -196.69
- Period
- 2024-03-31
- Total Revenue
- 252.48
- Selling/ General/ Admin Expenses Total
- 48.46
- Depreciation/ Amortization
- 6.84
- Other Operating Expenses Total
- 62.72
- Total Operating Expense
- 191.88
- Operating Income
- 60.6
- Net Income Before Taxes
- 62.72
- Net Income
- 46.56
- Diluted Normalized EPS
- 28
- Period
- 2024-03-31
- Period
- 2024-03-31
- Period
- 2023-12-31
- Total Revenue
- 309.97
- Selling/ General/ Admin Expenses Total
- 57.43
- Depreciation/ Amortization
- 6.92
- Other Operating Expenses Total
- 60.5
- Total Operating Expense
- 215.24
- Operating Income
- 94.73
- Net Income Before Taxes
- 99.72
- Net Income
- 72.07
- Diluted Normalized EPS
- 43.4
- Period
- 2023-12-31
- Total Assets
- 1077.05
- Total Liabilities
- 271.17
- Total Equity
- 805.88
- Tangible Book Valueper Share Common Eq
- 485.07
- Period
- 2023-12-31
- Cashfrom Operating Activities
- 74.63
- Cashfrom Investing Activities
- -4.54
- Cashfrom Financing Activities
- -84.55
- Net Changein Cash
- -14.46
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
Procter & Gamble Health Technical
Moving Average
SMA
- 5 Day5902.75
- 10 Day5897.54
- 20 Day5809.21
- 50 Day5462.75
- 100 Day5362.15
- 300 Day5331.95
Procter & Gamble Health Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Granules India
- 496.8
- -0.35
- -0.07
- 724.55
- 412.05
- 12033.96
- Marksans Pharma
- 253.15
- 6.05
- 2.45
- 358.5
- 158.25
- 11476.49
- Procter & Gamble Health
- 5905.15
- 28.85
- 0.49
- 6107.55
- 4912.3
- 9888.51
- Shilpa Medicare
- 861.2
- -8.3
- -0.95
- 1003.2
- 530.5
- 8421.75
- Strides Pharma Science
- 896.4
- 10.3
- 1.16
- 906.9
- 412.71
- 8210.97
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- Granules India
- 25.2
- 3.24
- 17.54
- 11.64
- Marksans Pharma
- 29.41
- 4.54
- 18.54
- 14.58
- Procter & Gamble Health
- 44.62
- 18.06
- -
- -
- Shilpa Medicare
- 86.77
- 3.54
- 3.27
- 5.17
- Strides Pharma Science
- 23.26
- 3.2
- -1.22
- -1.07
Procter & Gamble Health Shareholding
Shareholding Pattern
Shareholding Trend
Shareholding(%) v/s Date
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 29-May-25
- Audited Results & Final Dividend
- 12-Feb-25
- Quarterly Results & Interim Dividend
- 04-Nov-24
- Quarterly Results
- 21-Aug-24
- Audited Results & Final Dividend
- 02-May-24
- Quarterly Results
- 06-Feb-24
- Quarterly Results & Interim Dividend
- 03-Nov-23
- Quarterly Results
- 23-Aug-23
- Audited Results & Final Dividend
- 15-May-23
- Quarterly Results
- 08-Feb-23
- Quarterly Results & Interim Dividend
- Meeting Date
- Announced on
- Purpose
- 11-Apr-25
- 10-Mar-25
- POM
- 05-Dec-24
- 22-Aug-24
- AGM
- 21-Nov-23
- 24-Aug-23
- AGM
- 12-May-23
- 10-Apr-23
- POM
- 24-Mar-23
- 21-Feb-23
- POM
- Announced on
- Record Date
- Ex-Dividend
- Dividend Value
- 29-May-25
- -
- -
- 45
- 31-Jan-25
- 21-Feb-25
- 21-Feb-25
- 80
- 22-Aug-24
- -
- 28-Nov-24
- 60
- 25-Jan-24
- 14-Feb-24
- 14-Feb-24
- 50
- 26-Jan-24
- 14-Feb-24
- 14-Feb-24
- 150
- 24-Aug-23
- -
- 23-Nov-23
- 50
- 16-Jan-23
- 13-Feb-23
- 13-Feb-23
- 45
- 29-Aug-22
- -
- 15-Nov-22
- 11.5
- 29-Apr-22
- 13-May-22
- 12-May-22
- 41
- 26-Aug-21
- -
- 02-Nov-21
- 40


